Skip to Content

Darolutamide – A viable long-term treatment for nmCRPC

Data presented at ASCO GU 2023 concludes that patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) can safely stay on darolutamide as a viable long-term treatment.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top